Chronic Idiopathic Constipation Drugs Market Growth Offers Room to Grow

Stratview Research has published a new report titled “Chronic Idiopathic Constipation (CIC) Drugs Market” which is segmented By Product Type (Lubiprostone, Linaclotide, Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others), and Region.

As per the study, the Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.38 billion in 2021 to USD 6.93 billion by 2028 at a CAGR of around 6.72% during the forecast period of 2022-2028.

Report Highlights

This report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can affect the market dynamics of the industry. It provides thorough analysis of the market segments which include products, applications, and competitor analysis.

The market is bifurcated into various segments. Below given is the segment-wise analysis -

By end-user, the chronic idiopathic constipation (CIC) drugs market has been bifurcated into hospitals & clinics, ambulatory surgical centers, long-term care centers, and others. Under these, the hospitals & clinics segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period.

By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of chronic constipation particularly among the geriatric populace coupled with the presence of key market players such as Actavis Generics (US) and Pfizer Inc. (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding CIC drugs coupled with the rising geriatric population in developing countries, particularly China and India.

Who are the Key Players in the Market?

This report provides market intelligence in the most comprehensive way. It also provides critical insights into the key players active in the market, that will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key players activen in the Chronic Idiopathic Constipation (CIC) Drugs Market:

• Actavis Generics (US)
• The Chugai Pharmaceutical Co., Ltd (Japan)
• Ferring International Center, S.A. (Switzerland)
• Synergy Pharmaceuticals (US)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• F. Hoffmann-La Roche AG (Switzerland)
• Sanofi S.A. (France)
• Bayer AG (Germany)
• Salix Pharmaceuticals, Inc. (US)
• Sucampo Pharmaceuticals, Inc. (US)
• Ironwood Pharmaceuticals, Inc (US)
• Progenics Pharmaceuticals, Inc. (US).

Request a sample here- https://www.stratviewresearch.com/Request-Sample/2406/Chronic-Idiopathic-Constipation-(CIC)-Drugs-Market.html#form

Custom Research:

Stratview research delivers custom research services across the sectors. In case of any custom research requirements, please send your inquiry to sales@stratviewresearch.com. Or connect with our experts at +1-313-307-4176.

About Us

Stratview Research is a global market research firm, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with insightful market data to aid strategic decision making. These exclusive reports are the result of exclusive research methodology and are available for key industries such as chemicals, composites, advanced materials, technology, renewable energy, and more.

Article source: https://article-realm.com/article/Finance/33831-Chronic-Idiopathic-Constipation-Drugs-Market-Growth-Offers-Room-to-Grow.html